

Yusuke Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4551502/publications.pdf>

Version: 2024-02-01

105
papers

1,840
citations

218677

26
h-index

330143

37
g-index

112
all docs

112
docs citations

112
times ranked

3358
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy. Japanese Journal of Clinical Oncology, 2022, 52, 128-133.	1.3	0
2	Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. Pharmaceuticals, 2022, 15, 124.	3.8	4
3	<i>TP53</i> variants in p53 signatures and the clonality of STICs in RRSO samples. Journal of Gynecologic Oncology, 2022, 33, .	2.2	7
4	Development of a prognostic prediction support system for cervical intraepithelial neoplasia using artificial intelligence-based diagnosis. Journal of Gynecologic Oncology, 2022, 33, .	2.2	3
5	Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer. International Journal of Clinical Oncology, 2022, 27, 1644-1650.	2.2	4
6	Evaluation of preoperative prediction of intestinal invasion in patients with ovarian cancer. International Journal of Gynecology and Obstetrics, 2021, 153, 398-404.	2.3	0
7	Evaluating the importance of routine drainage following laparoscopic pelvic lymph node dissection for gynecological malignancies. International Journal of Gynecology and Obstetrics, 2021, 153, 438-442.	2.3	0
8	Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution. Japanese Journal of Clinical Oncology, 2021, 51, 213-217.	1.3	5
9	Time for enhancing government-led primary prevention of cervical cancer. Journal of Gynecologic Oncology, 2021, 32, e12.	2.2	4
10	Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. Journal of Personalized Medicine, 2021, 11, 403.	2.5	4
11	Two Components of Variant Profiles in Primary Vaginal Carcinosarcoma via Next-Generation Sequencing and a Literature Review. International Journal of Surgical Pathology, 2021, , 106689692110379.	0.8	1
12	Current status and future directions of ovarian cancer prognostic models. Journal of Gynecologic Oncology, 2021, 32, e34.	2.2	6
13	Hysteroscopic treatment assisted by photodynamic diagnosis for atypical polypoid adenomyoma: A report of two cases. Photodiagnosis and Photodynamic Therapy, 2021, 36, 102583.	2.6	1
14	Massive Hemorrhage Due to Cervical Endometriotic Cyst Rupture: Two Case Reports and a Literature Review. American Journal of Case Reports, 2021, 22, e934120.	0.8	2
15	Usefulness of Endoscopy for Female Genital Plastic Surgery: A Series of 4 Cases with Genital Malformations. American Journal of Case Reports, 2021, 22, e934363.	0.8	0
16	Risk-Reducing Salpingo-oophorectomy (RRSO). , 2021, , 183-191.		0
17	Hysteroscopic Photodynamic Diagnosis Using 5-Aminolevulinic Acid: A High-Sensitivity Diagnostic Method for Uterine Endometrial Malignant Diseases. Journal of Minimally Invasive Gynecology, 2020, 27, 1087-1094.	0.6	4
18	Primary malignant melanoma of the uterine cervix or vagina which were successfully treated with nivolumab. Journal of Obstetrics and Gynaecology Research, 2020, 46, 190-195.	1.3	15

#	ARTICLE	IF	CITATIONS
19	LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e11.	2.2	36
20	Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience. <i>Journal of Ovarian Research</i> , 2020, 13, 105.	3.0	9
21	Evaluation of safety and diagnostic performance for flexible hysteroscopy in 1591 outpatient cases. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1157-1161.	1.3	1
22	Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 643-652.	1.3	5
23	Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e19.	2.2	24
24	Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e65.	2.2	10
25	Cowden syndrome complicated by schizophrenia: A first clinical report. <i>European Journal of Medical Genetics</i> , 2020, 63, 103959.	1.3	1
26	Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?. <i>European Journal of Cancer Prevention</i> , 2019, 28, 562-567.	1.3	11
27	Atypical polypoid adenomyoma treated by hysteroscopy with photodynamic diagnosis using 5-aminolevulinic acid: A case report. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 27, 295-297.	2.6	7
28	Laparoscopic Surgery for Ovarian Cyst Infection with Avoidance of Ureteral Injury and Uterine Perforation following Intrauterine Insemination after Abdominal Modified Radical Trachelectomy. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-4.	0.3	0
29	Profiling of the Causative Bacteria in Infected Lymphocysts after Lymphadenectomy for Gynecologic Cancer by Pyrosequencing the 16S Ribosomal RNA Gene Using Next-Generation Sequencing Technology. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2019, 2019, 1-5.	1.5	2
30	Mutations of RAS genes in endometrial polyps. <i>Oncology Reports</i> , 2019, 42, 2303-2308.	2.6	7
31	Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins. <i>Cell Death and Disease</i> , 2019, 10, 876.	6.3	36
32	Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e10.	2.2	28
33	Warburg effect in Gynecologic cancers. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 542-548.	1.3	20
34	Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers. <i>Breast Cancer</i> , 2018, 25, 141-150.	2.9	19
35	Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 479-484.	1.0	5
36	Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e29.	2.2	11

#	ARTICLE	IF	CITATIONS
37	Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer. Japanese Journal of Clinical Oncology, 2017, 47, 401-406.	1.3	4
38	Carcinoma of the lower uterine segment diagnosed with Lynch syndrome based on <i>MSH6</i> germline mutation: A case report. Journal of Obstetrics and Gynaecology Research, 2017, 43, 416-420.	1.3	2
39	Aberrant chromatin remodeling in gynecological cancer (Review). Oncology Letters, 2017, 14, 5107-5113.	1.8	8
40	New use of microsatellite instability analysis in endometrial cancer. Oncology Letters, 2017, 14, 3297-3301.	1.8	34
41	Recent advances in the molecular mechanisms of Mayer-Rokitansky-Küster-Hauser syndrome. Biomedical Reports, 2017, 7, 123-127.	2.0	9
42	SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma. Scientific Reports, 2017, 7, 14574.	3.3	7
43	Radiation-induced angiosarcoma of the omentum diagnosed by laparoscopy: A case report. Molecular and Clinical Oncology, 2017, 8, 264-268.	1.0	1
44	Recent findings on epigenetic gene abnormalities involved in uterine cancer. Molecular and Clinical Oncology, 2017, 7, 733-737.	1.0	0
45	Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget, 2017, 8, 72147-72156.	1.8	49
46	Cost-effectiveness of surveillance and prevention strategies in BRCA 1/2 mutation carriers.. Journal of Clinical Oncology, 2017, 35, e13051-e13051.	1.6	0
47	Evaluation of vaginal delivery for twin pregnancy. Clinical and Experimental Obstetrics and Gynecology, 2017, 44, 591-594.	0.2	0
48	Methylation Analysis of DNA Mismatch Repair Genes Using DNA Derived from the Peripheral Blood of Patients with Endometrial Cancer: Epimutation in Endometrial Carcinogenesis. Genes, 2016, 7, 86.	2.4	8
49	Characterization of the STK11 splicing variant as a normal splicing isomer in a patient with Peutz-Jeghers syndrome harboring genomic deletion of the STK11 gene. Human Genome Variation, 2016, 3, 16002.	0.7	4
50	Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1613-1617.	1.3	5
51	Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. Oncology Letters, 2016, 11, 1287-1293.	1.8	29
52	ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncology Reports, 2016, 35, 607-613.	2.6	136
53	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. Journal of Biological Chemistry, 2016, 291, 9690-9699.	3.4	45
54	Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. International Journal of Oncology, 2015, 46, 1498-1506.	3.3	41

#	ARTICLE	IF	CITATIONS
55	Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer. <i>Scientific World Journal</i> , The, 2015, 2015, 1-10.	2.1	28
56	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. <i>Clinical Cancer Research</i> , 2015, 21, 4652-4662.	7.0	48
57	Clinicopathologic Analysis With Immunohistochemistry for DNA Mismatch Repair Protein Expression in Synchronous Primary Endometrial and Ovarian Cancers. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 440-446.	2.5	37
58	MicroRNAs in endometrial cancer: recent advances and potential clinical applications. <i>EXCLI Journal</i> , 2015, 14, 190-8.	0.7	46
59	Glycan profiling of gestational choriocarcinoma using a lectin microarray. <i>Oncology Reports</i> , 2014, 31, 1121-1126.	2.6	13
60	A tumor of the uterine cervix with a complex histology in a Peutz-Jeghers syndrome patient with genomic deletion of the <i>STK11</i> exon 1 region. <i>Future Oncology</i> , 2014, 10, 171-177.	2.4	8
61	Features of ovarian cancer in Lynch syndrome (Review). <i>Molecular and Clinical Oncology</i> , 2014, 2, 909-916.	1.0	63
62	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , 2014, 45, 691-700.	2.0	63
63	Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model. <i>Neuro-Oncology</i> , 2014, 16, 1048-1056.	1.2	43
64	Hereditary Endometrial Cancer: Lynch Syndrome. <i>Current Obstetrics and Gynecology Reports</i> , 2013, 2, 11-18.	0.8	3
65	Indocyanine green fluorescence imaging in the pregnant cynomolgus macaque: childbearing is supported by a unilateral uterine artery and vein alone?. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1309-1315.	1.7	11
66	Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer: comparison of magnetic resonance imaging and frozen sections. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 525-535.	2.8	21
67	Gene expression profile of a newly established choriocarcinoma cell line, iC3-1, compared to existing choriocarcinoma cell lines and normal placenta. <i>Placenta</i> , 2013, 34, 110-118.	1.5	10
68	Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. <i>Biomedical Reports</i> , 2013, 1, 335-340.	2.0	25
69	Candidate Biomarkers for Genetic and Clinicopathological Diagnosis of Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12123-12137.	4.1	23
70	Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). <i>Oncology Letters</i> , 2013, 6, 1184-1188.	1.8	44
71	Current status of molecular-targeted drugs for endometrial cancer (Review). <i>Molecular and Clinical Oncology</i> , 2013, 1, 799-804.	1.0	17
72	New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review). <i>Oncology Reports</i> , 2013, 29, 855-860.	2.6	26

#	ARTICLE	IF	CITATIONS
73	Abstract A63: Rsf-1, a chromatin remodeling protein, interacts with shelterin protein hRap1 and induces telomere shortening. , 2013, , .		0
74	Narrow band imaging in gynecology: A new diagnostic approach with improved visual identification (Review). International Journal of Oncology, 2012, 40, 350-6.	3.3	7
75	Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by Epigenetics. Biochemistry Research International, 2012, 2012, 1-5.	3.3	24
76	Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics, 2012, 4, 147-162.	2.1	36
77	Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome. International Journal of Oncology, 2012, 41, 793-797.	3.3	46
78	Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells. Oncology Reports, 2012, 28, 1146-1152.	2.6	25
79	Biomarkers in endometrial cancer: Possible clinical applications (Review). Oncology Letters, 2012, 3, 1175-1180.	1.8	35
80	Relationship of lower uterine segment cancer with Lynch syndrome: A novel case with an hMLH1 germline mutation. Oncology Reports, 2012, 28, 1537-1543.	2.6	19
81	Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review). International Journal of Oncology, 2012, 40, 1755-62.	3.3	28
82	Lobular endocervical glandular hyperplasia and peritoneal pigmentation associated with Peutzâ€Jeghers syndrome due to a germline mutation of STK11. Annals of Oncology, 2012, 23, 2990-2992.	1.2	30
83	Aberrant DNA Methylation in Endometrial Cancer. , 2012, , 471-480.		0
84	LATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progression. Journal of Cell Biology, 2012, 197, 625-641.	5.2	51
85	Metformin: A possible drug for treatment of endometrial cancer. Open Journal of Obstetrics and Gynecology, 2012, 02, 1-6.	0.2	8
86	Epigenetic Aberrant Hypermethylation of DNA in Endometrial Cancer: Application as a Biomarker. Journal of Cancer Therapy, 2011, 02, 610-615.	0.4	0
87	Establishment of a Choriocarcinoma Model from Immortalized Normal Extravillous Trophoblast Cells Transduced with HRASV12. American Journal of Pathology, 2011, 179, 1471-1482.	3.8	17
88	Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome. Current Genomics, 2011, 12, 25-29.	1.6	28
89	Narrow band imaging hysteroscopy: A comparative study using randomized video images. International Journal of Oncology, 2011, 39, 1057-62.	3.3	2
90	The cell cycle regulator Cdh1 controls the pool sizes of hematopoietic stem cells and mature lineage progenitors by protecting from genotoxic stress. Cancer Science, 2011, 102, 967-974.	3.9	13

#	ARTICLE	IF	CITATIONS
91	Flexible hysteroscopy with narrow band imaging (NBI) for endoscopic diagnosis of malignant endometrial lesions. <i>International Journal of Oncology</i> , 2011, 38, 613-8.	3.3	7
92	Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer. <i>Molecular Biology International</i> , 2011, 2011, 1-6.	1.7	17
93	Atypical Polypoid Adenomyoma (APAM) of the Uterine: Relationship with Endometrial Cancer. <i>Journal of Cancer Therapy</i> , 2011, 02, 458-462.	0.4	2
94	Gynecological tumors in patients with Peutz-Jeghers syndrome (PJS). <i>Open Journal of Genetics</i> , 2011, 01, 65-69.	0.1	8
95	The Anaphase-Promoting Complex/Cyclosome Activator Cdh1 Modulates Rho GTPase by Targeting p190 RhoGAP for Degradation. <i>Molecular and Cellular Biology</i> , 2010, 30, 3994-4005.	2.3	31
96	MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications (Review). <i>Oncology Letters</i> , 2010, 1, 935-940.	1.8	44
97	Presence of Circadian oscillation of Multidrug Resistance Gene 1 in KB-C2 cell line. <i>Annals of Cancer Research and Therapy</i> , 2010, 18, 13-18.	0.3	0
98	Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. <i>International Journal of Oncology</i> , 2009, 35, 977-82.	3.3	20
99	Fibroma of the Omentum Resembling an Ovarian Tumor in the Pelvis. <i>Keio Journal of Medicine</i> , 2009, 58, 234-236.	1.1	6
100	Epigenetic DNA hypermethylation: Clinical applications in endometrial cancer (Review). <i>Oncology Reports</i> , 2009, 22, 967-72.	2.6	33
101	Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. <i>International Journal of Oncology</i> , 2009, 34, 1541-7.	3.3	22
102	Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review). <i>Current Genomics</i> , 2009, 10, 127-132.	1.6	23
103	Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. <i>International Journal of Oncology</i> , 2007, 31, 713.	3.3	15
104	Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. <i>International Journal of Oncology</i> , 2007, 31, 713-20.	3.3	22
105	DNA Mismatch Repair (MMR) Genes and Endometrial Cancer. , 0, , .		1